E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to determined the maximum tolerated dose (MTD), safety and tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor effect of E7080 administered continually twice daily in combination with carboplatin and paclitaxel to patients with advanced or metastatic non-small cell lung cancer.
Non-small-cell Lung Cancer
DRUG: E7080|DRUG: E7080|DRUG: Paclitaxel|DRUG: Carboplatin
Maximum Tolerated Dose (MTD), Tolerability was confirmed by the frequency of occurrence of Dose Limiting Toxicities (DLTs) observed by the end of Cycle 1 in 6 participants., 7 days during the run-in period (Cycle 0) and 3 weeks (21 days) from Cycle 1
Anti-tumor Effect of E7080 in Combination With Carboplatin and Paclitaxel., At Screening, on Day 22 of every even cycle, and at discontinuation|Pharmacokinetics and Pharmacodynamics of E7080 in Combination With Carboplatin and Paclitaxel., At various time points until Day 22 of Cycle 1|To Evaluate the Safety and Tolerability of E7080 in Combination With Carboplatin and Paclitaxel., Refer safety section for safety analysis, Throughout the study until 30 days after last dose
The purpose of this study is to determined the maximum tolerated dose (MTD), safety and tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor effect of E7080 administered continually twice daily in combination with carboplatin and paclitaxel to patients with advanced or metastatic non-small cell lung cancer.